Heparin bridging vs. uninterrupted oral anticoagulation in patients with atrial fibrillation undergoing coronary artery stenting -results from the AFCAS registry -

Circulation Journal

Volumn 76, Issue 6, 2012, Pages 1363-1368

  Lahtela, Heli ^a   Rubboli, Andrea ^f   Schlitt, Axel ^g   Karjalainen, Pasi P ^b   Niemelä, Matti ^c   Vikman, Saila ^d   Puurunen, Marja ^e   Weber, Michael ^h   Valencia, Josè ⁱ   Biancari, Fausto ^c   Lip, Gregory Y H ^j   Airaksinen, K E Juhani ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b SATAKUNTA CENTRAL HOSPITAL   (Finland)

^c OULU UNIVERSITY HOSPITAL   (Finland)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f MAGGIORE HOSPITAL   (Italy)

^g MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^h KERCKHOFF HEART CENTER   (Germany)

ⁱ UNIVERSITY OF ALICANTE   (Spain)

^j UNIVERSITY OF BIRMINGHAM   (United Kingdom)

more..

Author keywords

Bleeding; Stents; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLEEDING; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; CLINICAL TRIAL (TOPIC); CORONARY STENT; DEATH; DRUG SAFETY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; REVASCULARIZATION; SIDE EFFECT; STABLE ANGINA PECTORIS; STENT THROMBOSIS; STROKE;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON, CORONARY; ANTICOAGULANTS; ATRIAL FIBRILLATION; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; DRUG ADMINISTRATION SCHEDULE; DRUG SUBSTITUTION; EUROPE; FEMALE; HEMORRHAGE; HEPARIN; HUMANS; LOGISTIC MODELS; MALE; MYOCARDIAL INFARCTION; ODDS RATIO; PROPENSITY SCORE; PROSPECTIVE STUDIES; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; STENTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84861733232     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-1206     Document Type: Article

References (21)

1. Rubboli A, Halperin J, Airaksinen K, Buerke M, Eeckhout E, Freedman S, et al. Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting: An expert consensus document with focus on atrial fibrillation. Ann Med 2008; 40: 428-436.
2. Lip G, Huber K, Andreotti F, Arnesen H, Airaksinen J, Cuisset T, et al. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: Executive summary: A Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2010; 31: 1311-1318.
3. Gao F, Zhou YJ, Wang ZJ, Shen H, Liu XL, Nie B, et al. Comparison of different antithrombotic regimens for patients with atrial fibrillation undergoing drug-eluting stent implantation. Circ J 2010; 74: 701-708.
4. Atarashi H, Inoue H, Okumura K, Yamashita T, Kumagai N, Origasa H, et al. Present status of anticoagulation treatment in Japanese patients with atrial fibrillation: A report from the J-RHYTHM Registry. Circ J 2011; 75: 1328-1333.
5. Airaksinen K, Schlitt A, Rubboli A, Karjalainen P, Lip G. How to manage antithrombotic treatment during percutaneous coronary interventions in patients receiving long-term oral anticoagulation: To "bridge" or not to "bridge"? EuroIntervention 2010; 6: 520-526.
6. Jamula E, Lloyd N, Schwalm J, Airaksinen K, Douketis J. Safety of uninterrupted anticoagulation in patients requiring elective coronary angiography with or without percutaneous coronary intervention: A systematic review and metaanalysis. Chest 2010; 138: 840-847.
7. Karjalainen P, Vikman S, Niemelä M, Porela P, Ylitalo A, Vaittinen M, et al. Safety of percutaneous coronary intervention during uninterrupted oral anticoagulant treatment. Eur Heart J 2008; 29: 1001-1010.
8. Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial: Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988; 11: 1-11.
9. Cutlip D, Windecker S, Mehran R, Boam A, Cohen D, van Es G, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115: 2344-2351.
10. Tolosana J, Berne P, Mont L, Heras M, Berruezo A, Monteagudo J, et al. Preparation for pacemaker or implantable cardiac defibrillator implants in patients with high risk of thrombo-embolic events: Oral anticoagulation or bridging with intravenous heparin? A prospective randomized trial. Eur Heart J 2009; 30: 1880-1884.
11. Wazni O, Beheiry S, Fahmy T, Barrett C, Hao S, Patel D, et al. Atrial fibrillation ablation in patients with therapeutic international normalized ratio: Comparison of strategies of anticoagulation management in the periprocedural period. Circulation 2007; 116: 2531-2534.
12. Jamula E, Douketis J, Schulman S. Perioperative anticoagulation in patients having implantation of a cardiac pacemaker or defibrillator: A systematic review and practical management guide. J Thromb Haemost 2008; 6: 1615-1621.
13. Annala A, Karjalainen P, Porela P, Nyman K, Ylitalo A, Airaksinen K. Safety of diagnostic coronary angiography during uninterrupted therapeutic warfarin treatment. Am J Cardiol 2008; 102: 386-390.
14. Wang T, Robinson L, Ou F, Roe M, Ohman E, Gibler W, et al. Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: Physician practice in the CRUSADE registry. Am Heart J 2008; 155: 361-368.
15. El-Jack S, Ruygrok P, Webster M, Stewart J, Bass N, Armstrong G, et al. Effectiveness of manual pressure hemostasis following transfemoral coronary angiography in patients on therapeutic warfarin anticoagulation. Am J Cardiol 2006; 97: 485-488.
16. Chang R, Doherty T, Goldberg S. How does warfarin affect the activated coagulation time? Am Heart J 1998; 136: 477-479.
17. Hirsh J, Warkentin T, Shaughnessy S, Anand S, Halperin J, Raschke R, et al. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119(1 Suppl): 64S-94S.
18. Douketis J, Berger P, Dunn A, Jaffer A, Spyropoulos A, Becker R, et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(6 Suppl): 299S-339S.
19. Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G, et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007; 28: 230-268.
20. Bonow R, Carabello B, Kanu C, de Leon AJ, Faxon D, Freed M, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): Developed in collaboration with the Society of Cardiovascular Anesthesiologists: Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 2006; 114: e84-e231.
21. Bassand J, Hamm C, Ardissino D, Boersma E, Budaj A, Fernández-Avilés F, et al. Guidelines for the diagnosis and treatment of non-STsegment elevation acute coronary syndromes. Eur Heart J 2007; 28: 1598-1660.